Equities research analysts expect Qiagen N.V. (NASDAQ:QGEN) to announce earnings per share of $0.41 for the current quarter, according to Zacks. Two analysts have made estimates for Qiagen N.V.’s earnings, with the highest EPS estimate coming in at $0.42 and the lowest estimate coming in at $0.41. Qiagen N.V. reported earnings per share of $0.39 during the same quarter last year, which would suggest a positive year over year growth rate of 5.1%. The firm is expected to announce its next quarterly earnings report on Wednesday, February 7th.

On average, analysts expect that Qiagen N.V. will report full-year earnings of $1.25 per share for the current year, with EPS estimates ranging from $1.24 to $1.27. For the next year, analysts expect that the firm will post earnings of $1.39 per share, with EPS estimates ranging from $1.35 to $1.43. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Qiagen N.V..

Qiagen N.V. (NASDAQ:QGEN) last released its quarterly earnings data on Monday, November 6th. The company reported $0.32 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.32. The company had revenue of $364.00 million during the quarter, compared to the consensus estimate of $363.42 million. Qiagen N.V. had a net margin of 6.40% and a return on equity of 11.36%. Qiagen N.V.’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 EPS.

A number of research firms have commented on QGEN. Zacks Investment Research upgraded shares of Qiagen N.V. from a “hold” rating to a “buy” rating and set a $39.00 price objective for the company in a report on Tuesday, October 10th. Deutsche Bank AG reiterated a “buy” rating on shares of Qiagen N.V. in a report on Monday, July 24th. Bank of America Corporation reiterated a “neutral” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Qiagen N.V. in a report on Friday, July 21st. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a report on Friday, July 28th. Finally, Cowen and Company reiterated a “hold” rating and issued a $33.00 price objective on shares of Qiagen N.V. in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. Qiagen N.V. presently has a consensus rating of “Hold” and an average price target of $34.06.

Qiagen N.V. (QGEN) traded down $0.01 during mid-day trading on Friday, reaching $31.02. 731,325 shares of the company’s stock were exchanged, compared to its average volume of 966,672. The firm has a market cap of $7,160.00, a P/E ratio of 25.08, a price-to-earnings-growth ratio of 1.89 and a beta of 1.13. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.78 and a current ratio of 5.33. Qiagen N.V. has a 12 month low of $27.51 and a 12 month high of $36.34.

Several hedge funds and other institutional investors have recently made changes to their positions in QGEN. Atlanta Capital Management Co. L L C increased its holdings in Qiagen N.V. by 210.1% in the 3rd quarter. Atlanta Capital Management Co. L L C now owns 1,314,274 shares of the company’s stock valued at $41,400,000 after purchasing an additional 890,454 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Qiagen N.V. in the 2nd quarter valued at approximately $26,408,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Qiagen N.V. in the 2nd quarter valued at approximately $18,234,000. WINTON GROUP Ltd acquired a new stake in Qiagen N.V. in the 2nd quarter valued at approximately $15,088,000. Finally, Vanguard Group Inc. increased its holdings in Qiagen N.V. by 7.0% in the 2nd quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock valued at $202,986,000 after purchasing an additional 394,201 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

WARNING: This article was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/17/brokerages-anticipate-qiagen-n-v-qgen-to-post-0-41-earnings-per-share.html.

About Qiagen N.V.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Get a free copy of the Zacks research report on Qiagen N.V. (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.